Pfizer’s Mylotarg returns to market after seven-year hiatus
US regulators have issued a green light for Pfizer’s Mylotarg as a treatment for acute myeloid leukaemia (AML), seven years after the drug was with voluntarily withdrawn from the market.
Read More
